I-138

• Description:

  I-138 is an orally active, reversible inhibitor of USP1-UAF1 (IC50: 4.1 nM; Ki: 5.4 nM), structurally related to ML323 (HY-17543) . I-138 induces monoubiquitination of FANCD2 and PCNA in cells and eliminates USP1 autocleavage in cells[1].

• UNSPSC:

  12352005

• Target:

  Deubiquitinase

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/i-138.html

• Concentration:

  10mM

• Purity:

  99.75

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C1NC2=CN=C(C3=CC=CC=C3C(C)C)N=C2N1CC4=CC=C(C5=NC(C(F)(F)F)=CN5C)C=C4

• Molecular Formula:

  C26H23F3N6O

• Molecular Weight:

  492.50

• References & Citations:

  [1]Simoneau A, et al. Ubiquitinated PCNA Drives USP1 Synthetic Lethality in Cancer. Mol Cancer Ther. 2023 Feb 1;22 (2) :215-226.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [2098211-50-6]